Petco Health & Wellness Company, Inc.: Form 10-K for the period ended Feb 3, 2024
Filed with the SEC on Apr 3, 2024 and accepted by EDGAR at Apr 2, 2024, 22:42 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2024-02-03. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 12 months2023-01-29 to 2024-02-03 | $6.26bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 12 months2023-01-29 to 2024-02-03 | $3.90bn | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 12 months2023-01-29 to 2024-02-03 | $2.35bn | us-gaap:GrossProfit |
| Selling, general and administrative | 12 months2023-01-29 to 2024-02-03 | $2.31bn | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 12 months2023-01-29 to 2024-02-03 | −$1.18bn | us-gaap:OperatingIncomeLoss |
| Interest expense | 12 months2023-01-29 to 2024-02-03 | $150.9m | us-gaap:InterestExpense |
| Income tax | 12 months2023-01-29 to 2024-02-03 | −$27.6m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 12 months2023-01-29 to 2024-02-03 | −$1.28bn | us-gaap:NetIncomeLoss |
| Diluted EPS | 12 months2023-01-29 to 2024-02-03 | −$4.78 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 12 months2023-01-29 to 2024-02-03 | −$4.78 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 12 months2023-01-29 to 2024-02-03 | 267,549 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 12 months2023-01-29 to 2024-02-03 | $215.7m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months2023-01-29 to 2024-02-03 | $225.6m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2024-02-03 | $125.4m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2024-02-03 | $951.7m | us-gaap:AssetsCurrent |
| Total assets | At period end2024-02-03 | $5.36bn | us-gaap:Assets |
| Current liabilities | At period end2024-02-03 | $1.11bn | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2024-02-03 | $4.18bn | us-gaap:Liabilities |
| Long-term debt | At period end2024-02-03 | $1.58bn | us-gaap:LongTermDebtNoncurrent |
| Shareholders' equity | At period end2024-02-03 | $1.18bn | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0000950170-24-040516. Last ingested by Listed: Oct 24, 2026, 15:15 ET. Listed shows no prices and gives no investment advice.